Researchers at the University of Delaware Biotechnology Institute have formed the company Orphagenix with the explicit goal of advancing their patented technology to repair genes and cure rare diseases.
OrphageniX Inc., a new biotechnology company founded by University of Delaware researchers, has been established in Wilmington to develop and commercialize UD-patented technologies for repairing genes that cause rare, hereditary diseases such as sickle cell anemia and spinal muscular atrophy.
Eric Kmiec, professor of biological sciences, and Hetal Parekh-Olmedo, senior research associate, both in the UD College of Arts and Sciences, co-founded and incubated OrphageniX at UD’s Delaware Biotechnology Institute in the Delaware Technology Park in 2005.
Kmiec holds 14 UD patents for gene-editing technologies and is widely regarded as a pioneer in the field.
Kmiec and Parekh-Olmedo discovered a way to introduce a tiny fragment of DNA into a diseased cell to replace the defective portion, triggering the cell to heal itself.
This method, which focuses on correcting a patient’s genes to make their own proteins, offers a safer approach than treating a patient’s genes with foreign genes or protein replacements, and eventually may lead to cures for rare diseases, according to Michael Herr, president and chief executive officer of OrphageniX.
Press Release: New biotech company to commercialize novel UD gene-repair technology…
OrphageniX, Inc…
